New Monoclonal Antibodies to Defined Cell Surface Proteins on Human Pluripotent Stem Cells
2 1 39

Speakers:
  • Associate Professor, CSIRO Australian Regenerative Medicine Institute, Monash University
    Biography
      Dr. Andrew Laslett is a Research Team Leader with the CSIRO Manufacturing business unit, where he leads a human pluripotent stem cell biology research team; He also holds an Adjunct Associate Professor position with the Australian Regenerative Medicine Institute at Monash University and is an Honorary Senior Fellow with the School of BioSciences at Melbourne University. Since 2001, Andrew and his laboratory have focused on elucidating the complex biology of human embryonic stem cells (hESC), examined methods for the differentiation of hESC to renal progenitor cells and more recently begun comparing hESC to reprogrammed human cells termed induced pluripotent stem (iPS) cells. His laboratory is currently focused on exploiting the basic biology of these cell types to create novel cell lines and tools that enhance human pluripotent cell research translation within CSIRO, Australia and internationally. Prior to his current role with CSIRO, Andrew was a Senior Scientist and Group Leader of the Human Embryonic Stem Cell Technology Laboratory at the Australian Stem Cell Centre (ASCC) following Senior Research Fellow appointments in the Laboratory of Embryonic Stem Cell Biology and the Centre for Reproduction and Development, Monash Institute of Medical Research, Monash University. He obtained his BSc (Hons) and PhD (1996) from Monash University prior to undertaking postdoctoral positions in both Hong Kong and Philadelphia, USA.

    Abstract:

    The availability of well-characterised monoclonal antibodies (mAbs) detecting cell-surface epitopes on human pluripotent stem cells (hPSCs) provides useful research tools to investigate the cellular mechanisms underlying human pluripotency and states of cellular reprogramming. We recently described generation of seven new mAbs that detect cell surface proteins present on primed and naive human ES cells (hESCs) and human iPS cells (hiPSCs), confirming our previous prediction that these proteins were present on the cell surface of hPSCs. The mAbs all show a high correlation with POU5F1 (OCT4) expression and other hPSC surface markers (TRA-160 and SSEA-4) in hPSC cultures and detect rare OCT4 positive cells in differentiated cell cultures. In addition, we report that subsets of the seven new mAbs are also immunoreactive to specific human somatic cell populations. The mAbs reported here should accelerate the investigation of the nature of pluripotency, and enable development of robust cell separation and tracing technologies to enrich or deplete for hPSCs and other human stem and somatic cell types.


    Show Resources
    Loading Comments...
    Show Resources
    Event Countdown
    • 0 Days
    • 0 Hours
    • 0 Minutes
    • 0 Seconds